The pathogenesis of neurological immune-related adverse events following immune checkpoint inhibitor therapy. Magdalena Lerch
Semin Immunol. 2025 Apr 27;78:101956. doi: 10.1016/j.smim.2025.101956. Online ahead of print. ABSTRACT Cancer is a leading cause of morbidity and mortality worldwide. The development of immune checkpoint inhibitors (ICI) has revolutionised cancer therapy, and patients who were previously incurable can now have excellent responses. These therapies work by blocking inhibitory immune pathways, like cytotoxic T … Read more